• Mashup Score: 0

    In this conversation, Rahul and Charles Ryan discuss the AFT-19, PRESTO study of androgen annihilation in high-risk biochemically relapsed prostate cancer. PRESTO is looking at a finite duration of treatment for patients with a rising PSA after prior surgery in the biochemically recurrent, hormone-sensitive setting. There were three treatment arms. The standard of care was ADT monotherapy, the…

    Tweet Tweets with this article
    • Prolonging PSA progression-free survival with intensification of ADT, the #PRESTO study (AFT19). Rahul Aggarwal, MD @UCSFCancer and @charlesryanmd @PCFnews discuss whether intensification of ADT can really prolong PSA PFS. #WatchNow on UroToday > https://t.co/Sp0VyzFN6g https://t.co/tII2UEd8AU

  • Mashup Score: 1

    In this conversation, Rahul and Charles Ryan discuss the AFT-19, PRESTO study of androgen annihilation in high-risk biochemically relapsed prostate cancer. PRESTO is looking at a finite duration of treatment for patients with a rising PSA after prior surgery in the biochemically recurrent, hormone-sensitive setting. There were three treatment arms. The standard of care was ADT monotherapy, the…

    Tweet Tweets with this article
    • Prolonging PSA progression-free survival with intensification of ADT, the #PRESTO study (AFT19). Rahul Aggarwal, MD @UCSFCancer and @charlesryanmd @PCFnews discuss whether intensification of ADT can really prolong PSA PFS. #WatchNow on UroToday > https://t.co/Sp0VyzFN6g https://t.co/0edSLR6Pvx

  • Mashup Score: 0

    In this conversation, Rahul and Charles Ryan discuss the AFT-19, PRESTO study of androgen annihilation in high-risk biochemically relapsed prostate cancer. PRESTO is looking at a finite duration of treatment for patients with a rising PSA after prior surgery in the biochemically recurrent, hormone-sensitive setting. There were three treatment arms. The standard of care was ADT monotherapy, the…

    Tweet Tweets with this article
    • Prolonging PSA progression-free survival with intensification of ADT, the #PRESTO study (AFT19). Rahul Aggarwal, MD @UCSFCancer and @charlesryanmd @PCFnews discuss whether intensification of ADT can really prolong PSA PFS. #WatchNow on UroToday > https://t.co/Sp0VyzFN6g https://t.co/OEvotQEE6K

  • Mashup Score: 6

    In this conversation, Rahul and Charles Ryan discuss the AFT-19, PRESTO study of androgen annihilation in high-risk biochemically relapsed prostate cancer. PRESTO is looking at a finite duration of treatment for patients with a rising PSA after prior surgery in the biochemically recurrent, hormone-sensitive setting. There were three treatment arms. The standard of care was ADT monotherapy, the…

    Tweet Tweets with this article
    • Prolonging PSA progression-free survival with intensification of ADT, the #PRESTO study (AFT19). Rahul Aggarwal, MD @UCSFCancer and @charlesryanmd @PCFnews discuss whether intensification of ADT can really prolong PSA PFS. #WatchNow on UroToday > https://t.co/Sp0VyzGkVO https://t.co/UPijrgYnU5